Skip to main content
OpenTrials
Completed

NCT Number: NCT00697801

Study of MAP0010 in Asthmatic Children and Adolescents

The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

San Diego, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female asthmatic children/adolescents
  • 1 to 18 years of age
  • FEV1 greater than or equal to 50% predicted normal (where obtainable)
  • Stable but symptomatic
  • Diagnosis of asthma (per NIH criteria) at least 3 months before screening OR documented exacerbation or worsening of asthma or symptoms suggestive of asthma including nocturnal asthma, within 6 months of screening OR documented SAB use more than or at least once for symptom relief during the 4 days of run in with a total symptom score greater than or equal to 1 OR greater than or equal to 1 night disturbed due to asthma symptoms in previous month.

Exclusion criteria

  • Any other significant childhood illness.
  • Participated in any investigational clinical trial within the 30 days prior to screening.
  • Use of any corticosteroid within 2 weeks of screening.
  • Use of oral corticosteroid within 30 days of screening or prolonged use of oral corticosteroids within 12 weeks of screening.
  • Use of inhaled long acting bronchodilators.
  • Presumptive or documented history of upper or lower respiratory infection within 2 weeks before screening.
  • Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.
  • History suggestive (or diagnosis) of other concomitant lung disease.

Treatment and study plan

MAP0010 low dose

Drug

a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks

MAP0010 high dose

Drug

a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks

Placebo

Drug

Placebo delivered by nebulization twice daily for 6 weeks

Primary outcomes

  1. Change From Baseline in Daytime Composite Symptom Score

    Time frame: baseline, week 6

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.

    The individual symptoms were scored using a four point scale:

    0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms

    Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

  2. Change From Baseline in Nighttime Composite Symptom Score

    Time frame: baseline, week 6

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.

    The individual symptoms were scored using a four point scale:

    0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms

    Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Secondary outcomes

  1. Change From Baseline in FEV1% Predicted

    Time frame: baseline, week 6

    The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Collaborators

  • MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Registry information

Official study title

A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks

Important dates

Study start
2006
Primary completion
2006
Study completion
2006
First posted
Jun 16, 2008
Registry last updated
Jan 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.